Casey P. Eitner, President/CEO, has extensive experience starting and running successful new biotech businesses. Mr. Eitner served as VP Business Development & New Businesses at Life Technologies (Invitrogen). He was previously Executive VP of the Molecular Diagnostics Division, now Digene (DIGE), which pioneered DNA-based diagnostic tests for papillomavirus and cervical cancer. Biotech Venture Management LLC, which Mr. Eitner founded, has been providing senior management roles to early stage biotech companies in the US, Canada and Europe since 2000. He is also a director of CytoStore, Inc. a spin-off from the University of Calgary.
Lewis Parker, Board Director, is currently a director of DJ Orthopedics, Inc., (NYSE: DJO), a global orthopedic device company. He previously served as a director of Interpore International, Inc. (BONZ), and as director and CFO of American Osteomedix, an orthopedic products company sold to Interpore in 2001. Mr. Parker was President of Orthopedic Operations for Kirschner Medical Corporation (KMDC), acquired in 1994 by Biomet. At Hazleton Laboratories (HLC) he was CFO and later President of the American Laboratory subsidiary. Mr. Parker is currently a principal in Parkwood, LLC, a venture investing firm that was an early investor in EPI.
James Groninger, Board Director, is CEO of LBS Technologies, Inc., a private biotechnology company focusing on RNA amplification and cellular therapy, and an investor in EPI’s current Series A Preferred offering. Mr. Groninger founded and is President of The Bay South Company, a Richmond, Virginia-based provider of financial advisory and investment banking services. From 1988 through 1994, he served as a Managing Director, Investment Banking Division, of PaineWebber Inc., now UBS. Mr. Groninger is a member of the board of directors of NPS Pharmaceuticals, Inc. and Cygne Designs, Inc., both publicly held companies, and LBS Technologies. Mr. Groninger received an M.B.A. degree from Harvard Business School and a B.S. from Yale University. He is a CPA and a CFA.
Expression Pathology Inc. is a leader in tissue proteomics.
Using our tissue
analysis platform we are developing targeted tissue proteomic assays for oncology. The tests will provide information to guide treatment decisions – the
presence of protein drug targets, or which biological pathways are
activated in tumors to aid prognosis and drug selection.
Our scientists have extensive experience in pathology,
proteomics and tissue analysis. Call us to discuss your project. We can
help you design your experiment, and we can also help you with grant
writing.
The Liquid Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire protein
content. Mass spec friendly. Requires only 30,000 cells for multiple
mass spectrometry analyses.
The Director® Laser Microdissection Slides
provide the fastest, easiest and most accurate way
to collect specific cellular features from tissue sections. Engineered
for use with existing
Leica LMD and PALM Zeiss laser microdissection system.
Investors
We are seeking investments and collaboration opportunities.
For more information please contact our business development group.
b u s d e v @ e x p r e s s i o n p a t h o l o g y . c o m
Transcribe email address to standard format. Spam bots have made it impossible to post properly formatted
email addresses.
